May 2, 2024 | Access, clinical trials, digital health, digital tools, oncology, patient insight-gathering, reimbursement
With rapid growth comes growing pains…

The field of oncology is rapidly growing and evolving. In 2022, global spending on cancer medicines was approximately 196 billion USD, and this number is forecasted to reach $375 billion by 2027. In fact, for the past five years, the number of treated patients with cancer has seen an average annual increase of 5% globally (1). However, with rapid growth comes growing pains.
New competitors are entering the market at a rapid pace, and competition is intensifying. There are currently more than 2,000 oncology products under development. Emerging biopharma companies are responsible for over 70% of these products (up 20 percentage points from 2017) while Big Pharma has seen a declining share of the oncology pipeline, at only around 20% of products currently under development (down 15 percentage points from 2017). This competitive intensity tends to focus on smaller patient populations with multiple treatment options.
With a larger number of treatable patients, improving survival rates, more clinical trials, and increased focus on real-world evidence, the definition of ‘standard of care’ is continuously changing. As a result, treatment algorithms are becoming more complex, leading to variable uptake and use of new treatments across regions, clinics, and prescribers.
Further, the time advantage traditionally afforded to new cancer therapies has been substantially reduced due to advances in our understanding of the underlying tumor biology and the emergence of novel treatment modalities. Occasionally, the advantage disappears well before the period of exclusivity ends (2)…
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
In recent years, social media has evolved into an essential part of Pharma operations, for better or worse.
Lucy Jung, CEO & Founder of Charco Neurotech, shares how meeting members of the Parkinson’s community catalyzed the founding of Charco and how #innovative medical devices and software can improve…
Dr. Joshua Liu, Co-founder & CEO of SeamlessMD, explores how technology and “Digital Care Journeys” can help hospitals reduce the surgical backlog for high-volume procedures like hip and knee replacements,…
Virtual engagement experts helping life science companies have ongoing conversations with their customers through our best-in-class online collaboration tools. Best-In-Class CollaborationTechnology Impetus Digital provides two turn-key software solutions through the Impetus…
Lucy Jung, CEO & Founder of Charco Neurotech, shares how meeting members of the Parkinson’s community catalyzed the founding of Charco and how #innovative medical devices and software can improve…
About the AwardToronto, ON, December 15, 2022 — PM360, a leading trade magazine for marketing decision-makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named Impetus Digital’s Virtual…
Dr. Ittai Dayan, Co-founder & CEO of Rhino Health, shares how his company is transforming the way healthcare AI solutions are created, adopted and measured. He will also explore how…
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program.
Tip #8 – Do you make sure to have a host for all your virtual events? Check our top 10 tips to increase engagement during virtual events: https://www.impetusdigital.com/2021/03/25/top-10-tips-to-increase-engagement-during-virtual-events/
Savva Kerdemelidis, Founder & CEO of Crowd Funded Cures, explores the concepts of interventional pharmacoeconomics and pay-for-success contracts to fund new uses for off-patent drugs and other unmonopolizable therapies.
